Difference between revisions of "Pegylated liposomal doxorubicin (Doxil)"
m |
|||
| Line 25: | Line 25: | ||
*Brief patient counseling information can be found on [http://www.doxil.com/assets/DOXIL_PI_Booklet.pdf#page=15 page 15 of the Doxorubicin liposomal (Doxil) package insert]<ref name="insert"></ref> | *Brief patient counseling information can be found on [http://www.doxil.com/assets/DOXIL_PI_Booklet.pdf#page=15 page 15 of the Doxorubicin liposomal (Doxil) package insert]<ref name="insert"></ref> | ||
*[http://www.uptodate.com/contents/liposomal-doxorubicin-patient-drug-information Doxorubicin liposomal (Doxil) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/liposomal-doxorubicin-patient-drug-information Doxorubicin liposomal (Doxil) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/liposomal-doxorubicin-patient-drug-information Doxorubicin liposomal (Doxil) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/liposomal-doxorubicin-patient-drug-information Doxorubicin liposomal (Doxil) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | * 11/17/1995: Initial FDA approval | ||
==References== | ==References== | ||
| Line 34: | Line 37: | ||
[[Category:Topoisomerase inhibitors]] | [[Category:Topoisomerase inhibitors]] | ||
[[Category:Irritant chemotherapy]] | [[Category:Irritant chemotherapy]] | ||
| + | |||
| + | [[Category:Aggressive Non-Hodgkin lymphoma medications]] | ||
[[Category:Breast cancer medications]] | [[Category:Breast cancer medications]] | ||
[[Category:Esophageal cancer medications]] | [[Category:Esophageal cancer medications]] | ||
| + | [[Category:HIV-associated lymphoma medications]] | ||
[[Category:Hodgkin lymphoma medications]] | [[Category:Hodgkin lymphoma medications]] | ||
[[Category:Multiple myeloma medications]] | [[Category:Multiple myeloma medications]] | ||
[[Category:Ovarian cancer medications]] | [[Category:Ovarian cancer medications]] | ||
| + | [[Category:Sarcoma medications]] | ||
| + | [[Category:Uterine cancer medications]] | ||
| + | |||
| + | [[Category:Drugs FDA approved in 1995]] | ||
Revision as of 03:26, 12 November 2014
Also known as Caelyx or Myocet.
General information
Class/mechanism: Anthracycline; binds and intercalates into DNA, inhibiting nucleotide replication and DNA/RNA polymerase activity. Causes DNA cleavage through interaction with topoisomerase II.
Doxorubicin is encapsulated in long-circulating STEALTH® liposomes, which are microscopic vesicles made of a phospholipid bilayer. The liposomes are pegylated with surface-bound methoxypolyethylene glycol (MPEG) to increase circulation time and protect them from detection by the mononuclear phagocyte system (MPS). Their 100 nm size and long circulation may aid their ability to penetrate the altered vasculature of tumors. Exact mechanism of release of the active drug contained within the liposome is not understood.[1][2][3]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Aggressive Non-Hodgkin lymphoma
- Breast cancer
- Esophageal cancer
- HIV-associated lymphoma
- Hodgkin lymphoma
- Multiple myeloma
- Ovarian cancer
- Sarcoma
- Uterine cancer
Patient drug information
- Doxorubicin liposomal (Doxil) patient drug information (Chemocare)[4]
- Brief patient counseling information can be found on page 15 of the Doxorubicin liposomal (Doxil) package insert[1]
- Doxorubicin liposomal (Doxil) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 11/17/1995: Initial FDA approval
References
- Drug index
- Chemotherapy
- Anthracyclines
- Topoisomerase inhibitors
- Irritant chemotherapy
- Aggressive Non-Hodgkin lymphoma medications
- Breast cancer medications
- Esophageal cancer medications
- HIV-associated lymphoma medications
- Hodgkin lymphoma medications
- Multiple myeloma medications
- Ovarian cancer medications
- Sarcoma medications
- Uterine cancer medications
- Drugs FDA approved in 1995